Ki Chung, MD
Hematology & Oncology · Spartanburg, SCNPI 1336110113
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.6%. Among hematology & oncology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 557 payments — averaging $87.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Genentech USA, Inc.$6K
- E.r. Squibb & Sons, L.L.C.$5K
- Taiho Oncology, Inc.$4K
- Springworks Therapeutics, Inc.$3K
- Incyte Corporation$3K
- plus $21K from 54 others
Across 332 payments — averaging $14,074 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Biopharmaceuticals, Inc$2M
- Pfizer$1.1M
- Epizyme, Inc.$634K
- AbbVie$129K
- Seagen Inc.$124K
- Bayer$116K
- plus $557K from 16 others
What the payments were for
- Consulting fees$23,50448%
- Speaking & faculty fees$6,08513%
- Travel & lodging$1,2863%
- Food & beverage$15,20131%
- Education$1,2102%
- Other$1,2803%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,565 in reported general payments places this provider in the 90th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 23 | $517,644 |
| RevlimidLenalidomide | 15 | $255,426 |
| Lenalidomide | 17 | $254,383 |
| SprycelDasatinib | 12 | $208,429 |
| CalquenceAcalabrutinib Maleate | 14 | $204,272 |
| IbrancePalbociclib | 12 | $189,809 |
| VerzenioAbemaciclib | 13 | $188,258 |
| XtandiEnzalutamide | 12 | $164,181 |
| LonsurfTrifluridine/Tipiracil Hcl | 20 | $104,023 |
| JakafiRuxolitinib Phosphate | 12 | $91,562 |
| Deferiprone | 12 | $78,028 |
| VenclextaVenetoclax | 13 | $43,764 |
| XareltoRivaroxaban | 33 | $28,690 |
| Imatinib Mesylate | 12 | $27,051 |
| EliquisApixaban | 19 | $13,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $4,817 | $726,07335 claims |
| Bristol Myers SquibbRevlimid | $379 | $255,42615 claims |
| AstraZenecaCalquence | $7,581 | $204,27214 claims |
| PfizerIbrance, Eliquis | $892 | $203,36231 claims |
| Lilly USA, LLCVerzenio | $391 | $188,25813 claims |
| Astellas Pharma US IncXtandi | $435 | $164,18112 claims |
| Taiho Oncology, Inc.Lonsurf | $3,940 | $104,02320 claims |
| Incyte CorporationJakafi | $2,554 | $91,56212 claims |
| AbbVieVenclexta | $572 | $43,76413 claims |
| Johnson & JohnsonXarelto | $988 | $28,69033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Spartanburg
- Vikas DemblaSpartanburg$568K
- Tondre BuckSpartanburg$366K
- Kim Hont YeeSpartanburg$15K
- Michael HumeniukSpartanburg$12K
- James BeardenSpartanburg$11K
- Steven CorsoSpartanburg$10K
- Suzanne FanningGreenville$927K
- Stephen DyarGreenville$413K
- Kashyap PatelRock Hill$379K
- Bhumika PatelGreenville$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.